Skip to main content
CLAL Biotechnology Industries Ltd. logo

CLAL Biotechnology Industries Ltd. — Investor Relations & Filings

Ticker · CBI ISIN · IL0011042806 TA Financial and insurance activities
Open in API
Filings indexed 8 across all filing types
Latest filing 2023-01-08 Investor Presentation
Country IL Israel
Listing TA CBI

About CLAL Biotechnology Industries Ltd.

https://cbi.co.il/

Clal Biotechnology Industries Ltd. is a life sciences investment company focused on identifying, financing, and supporting innovative ventures. The company's investment portfolio is diversified across various stages of development, from pre-clinical and seed stages to emerging growth companies. Its primary areas of investment include biopharmaceuticals, therapeutics, diagnostics, and medical devices. The firm actively manages its portfolio companies, providing strategic guidance and support to foster their growth and development.

Recent filings

Filing Released Lang Actions
Corporate Presentation, January 2023
Investor Presentation Classification · 99% confidence The document is titled 'Corporate Presentation January 2023' and contains extensive slides detailing investment strategy, portfolio holdings, value generation metrics, pipeline catalysts, and specific company profiles (e.g., Elicio, eXIthera). This structure, content focus (strategy, financials overview, pipeline updates), and presentation format strongly indicate an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief announcement (RPA/RNS).
2023-01-08 English
Corporate Presentation, January 2023
Regulatory Filings Classification · 99% confidence The document text is very short (2497 characters) and contains metadata indicating a file name: 'CBI_Corporate_Presentation_January_2023_isa.pdf'. The title section mentions 'CLAL BIOTECHNOLOGY INDUSTRIES LTD' and the date 08/01/2023. The presence of 'Corporate Presentation' strongly suggests this document is an Investor Presentation (IP). Furthermore, the structure, including placeholders for signatures and a reference to a PDF file, indicates this is likely an announcement or cover page for the presentation, but given the context of financial filings, the core content being announced is the presentation itself. Since the document is short and seems to be announcing or containing the presentation material, 'Investor Presentation' (IP) is the most appropriate classification over a general 'Report Publication Announcement' (RPA), as the content type is clearly defined as a presentation.
2023-01-08 Russian
CBI-Presentation-February 2021
Investor Presentation Classification · 99% confidence The document is explicitly titled 'CORPORATE PRESENTATION FEBRUARY 2021' and contains extensive slides detailing investment approach, portfolio company performance, clinical development pipelines, and future catalysts. This structure is characteristic of an Investor Presentation (IP), which is designed to communicate strategy and performance updates to current and potential investors. It is not a formal regulatory filing like a 10-K, nor is it a short announcement of a report (RPA/RNS).
2021-02-14 English
CBI-Presentation-February 2021
Report Publication Announcement Classification · 98% confidence The document text is very short (2461 characters) and contains structured information typical of a regulatory filing announcement, including company name (CLAL BIOTECHNOLOGY INDUSTRIES LTD), filing date (14/02/2021), and references to attached files (e.g., *CBI-February-2021_isa.pdf*). Crucially, it announces the publication of a document related to the period ending 31/12/2020, but it does not contain the full content of a financial report (like a 10-K or IR). The structure strongly suggests an announcement about the release of a report, fitting the definition of a Report Publication Announcement (RPA).
2021-02-14 Russian
INVESTORS PRESENTATION,NOVEMBER 10,2020
Investor Presentation Classification · 98% confidence The document is titled 'CORPORATE PRESENTATION NOVEMBER 2020' and contains extensive slides detailing company strategy, portfolio companies, clinical trial readouts (Phase I, II, III), management team information, and future outlook ('WHAT TO LOOK FOR IN 2021'). This structure, combining high-level strategy with detailed pipeline updates and financial context, is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement (RPA/RNS). It is a comprehensive document designed to inform investors about the company's assets and progress.
2020-11-22 English
INVESTORS PRESENTATION,NOVEMBER 10,2020
Regulatory Filings Classification · 95% confidence The document text is highly fragmented and contains non-standard characters, suggesting it might be a raw text extraction from a structured filing, possibly a regulatory announcement or a cover page. Key indicators are the company name ("CLAL BIOTECHNOLOGY INDUSTRIES LTD"), a filing date ("22/11/2020"), and references to regulatory bodies/exchanges ("www.isa.gov.il", "www.tase.co.il"). The document length is very short (2461 characters). Crucially, it contains a section header that translates roughly to "Report Publication Announcement" or similar phrasing (based on context clues like the date/time stamp and the structure suggesting an accompanying file, e.g., "����� ���� *CBI-November-2020_isa.pdf*"). Since the text itself is not the full financial report but appears to be an announcement about a filing or report release, the most appropriate classification according to Rule 2 (Menu vs Meal) is Report Publication Announcement (RPA).
2020-11-22 Russian

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.